Advertisement
Most Shareholders Will Probably Agree With Quick Heal Technologies Limited's (NSE:QUICKHEAL) CEO Compensation
CEO Kailash Katkar has done a decent job of delivering relatively good performance at Quick Heal Technologies Limited (NSE:QUICKHEAL) recently. In light of this performance, CEO compensation will probably not be the main focus for shareholders as they go into the AGM on 06 August 2021. Here is our take on why we think the CEO compensation looks appropriate.
See our latest analysis for Quick Heal Technologies
Comparing Quick Heal Technologies Limited's CEO Compensation With the industry
Our data indicates that Quick Heal Technologies Limited has a market capitalization of ₹19b, and total annual CEO compensation was reported as ₹13m for the year to March 2021. That's mostly flat as compared to the prior year's compensation. In particular, the salary of ₹11.9m, makes up a huge portion of the total compensation being paid to the CEO.
On examining similar-sized companies in the industry with market capitalizations between ₹7.4b and ₹30b, we discovered that the median CEO total compensation of that group was ₹14m. So it looks like Quick Heal Technologies compensates Kailash Katkar in line with the median for the industry. What's more, Kailash Katkar holds ₹5.1b worth of shares in the company in their own name, indicating that they have a lot of skin in the game.
| Component | 2021 | 2020 | Proportion (2021) |
| Salary | ₹12m | ₹12m | 90% |
| Other | ₹1.3m | ₹1.3m | 10% |
| Total Compensation | ₹13m | ₹13m | 100% |
On an industry level, it's fascinating to see that all of total compensation represents salary and non-salary benefits do not factor into the equation at all. Quick Heal Technologies pays a modest slice of remuneration through salary, as compared to the broader industry. If salary dominates total compensation, it suggests that CEO compensation is leaning less towards the variable component, which is usually linked with performance.
Quick Heal Technologies Limited's Growth
Quick Heal Technologies Limited's earnings per share (EPS) grew 12% per year over the last three years. In the last year, its revenue is up 16%.
Shareholders would be glad to know that the company has improved itself over the last few years. It's a real positive to see this sort of revenue growth in a single year. That suggests a healthy and growing business. Although we don't have analyst forecasts, you might want to assess this data-rich visualization of earnings, revenue and cash flow.
Has Quick Heal Technologies Limited Been A Good Investment?
Quick Heal Technologies Limited has served shareholders reasonably well, with a total return of 17% over three years. But they probably wouldn't be so happy as to think the CEO should be paid more than is normal, for companies around this size.
To Conclude...
Seeing that the company has put up a decent performance, only a few shareholders, if any at all, might have questions about the CEO pay in the upcoming AGM. However, we still think that any proposed increase in CEO compensation will be examined closely to make sure the compensation is appropriate and linked to performance.
While CEO pay is an important factor to be aware of, there are other areas that investors should be mindful of as well. That's why we did some digging and identified 2 warning signs for Quick Heal Technologies that you should be aware of before investing.
Switching gears from Quick Heal Technologies, if you're hunting for a pristine balance sheet and premium returns, this free list of high return, low debt companies is a great place to look.
If you decide to trade Quick Heal Technologies, use the lowest-cost* platform that is rated #1 Overall by Barron’s, Interactive Brokers. Trade stocks, options, futures, forex, bonds and funds on 135 markets, all from a single integrated account. Promoted
Valuation is complex, but we're here to simplify it.
Discover if Quick Heal Technologies might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisThis article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
About NSEI:QUICKHEAL
Quick Heal Technologies
Engages in the provision of security software products and solutions to consumers, small businesses, government establishments, and corporate houses in India and internationally.
Flawless balance sheet with low risk.
Similar Companies
Market Insights
Advertisement
Weekly Picks
LO
Lou_Basenese on Optimi Health ·
The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist
Fair Value:US$1155.3% undervalued
49 followersusers have followed this narrative
2 commentsusers have commented on this narrative
8 likesusers have liked this narrative
WE
WealthAP on Novo Nordisk ·
Novo Nordisk (NVO): Is the "Easy Growth" Story Over?
Fair Value:DKK 407.7720.1% undervalued
69 followersusers have followed this narrative
0 commentsusers have commented on this narrative
8 likesusers have liked this narrative
VA
ValueInvestingSubstack on Zoetis ·
Zoetis down -50% over the past year
Fair Value:US$92.9217.2% undervalued
23 followersusers have followed this narrative
0 commentsusers have commented on this narrative
9 likesusers have liked this narrative
CE
CentryResearch on Centrus Energy ·
Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.
Fair Value:US$1907.4% undervalued
24 followersusers have followed this narrative
0 commentsusers have commented on this narrative
10 likesusers have liked this narrative
Recently Updated Narratives
FE
FernandoLeal on Compass Gas e Energia ·
Compass Gas e Energia has a reliable dividend, with a consistent moat, high free cash flow margins and will expand to two digits net margin.
Fair Value:R$40.9439.5% undervalued
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
BR
Brunhilde_Wagner on Copart ·
Compounder to Cash Generator in Real Time
Fair Value:US$2710.3% overvalued
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
WI
WisetoWealth on PayPal Holdings ·
The Underrated Transformation of a Digital Payments Giant
Fair Value:US$90.3137.9% undervalued
5 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Popular Narratives
CU
CubanEros on Microsoft ·
A wonderful business at reasonable price.
Fair Value:US$419.917.3% undervalued
84 followersusers have followed this narrative
0 commentsusers have commented on this narrative
6 likesusers have liked this narrative
OS
oscargarcia on NVIDIA ·
The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.
Fair Value:US$28029.8% undervalued
192 followersusers have followed this narrative
9 commentsusers have commented on this narrative
15 likesusers have liked this narrative
BE
benjamin_lvieq on PayPal Holdings ·
PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback
Fair Value:US$6513.7% undervalued
72 followersusers have followed this narrative
2 commentsusers have commented on this narrative
11 likesusers have liked this narrative
Trending Discussion
DE
derek_3wsdg on Teladoc Health ·
You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.
1
|0
